HLB Pharmaceutical Co., Ltd. (KOSDAQ: 047920)
South Korea flag South Korea · Delayed Price · Currency is KRW
23,200
-200 (-0.85%)
Dec 19, 2024, 3:00 PM KST

HLB Pharmaceutical Company Description

HLB Pharmaceutical Co., Ltd., a pharmaceutical company, researches and develops peptide drugs in South Korea.

The company offers skeletal muscle relaxants, tranquilizers, antihistamines, antihypertensive agents, pain relief, antipruritics, astringents, anti-inflammatories, alimentary system drugs, metabolic drugs, ophthalmic agents, local anesthetics, antiarteriosclerotic agents, expectorants, antipyretics, analgesics, antidiabetic drug, chemotherapeutics, peptic ulcer agents, central nervous system drug, antibiotics, digestives, antacids, dental drugs, multivitamins, parasistic skin disese drugs, dermatlogicals, agents for urogenital organ, amino acid agent, antitussive, mucolytic agents, anthelmintics, antidiarrheals, circulatory system drug, vitamins, skin softeners, anti-hemorrhoid drugs, and agents for liver disease.

It is also developing CTT-004 for the treatment of ataxia induced by spinocerebellar degeneration; and offers CMO services.

The company was formerly known as Mediforum Pharmaceutical Incorporation and changed its name to HLB Pharmaceutical Co., Ltd in October 2020.

HLB Pharmaceutical Co., Ltd. was founded in 1998 and is headquartered in Namyangju-si, South Korea.

HLB Pharmaceutical Co., Ltd.
Country South Korea
Founded 1998
Industry Pharmaceutical Preparations
CEO Jae-hyeong Park

Contact Details

Address:
27, Gyeonggang-ro
Namyangju-si, 12244
South Korea
Phone 82 3 1557 0001
Website hlbpharma.co.kr

Stock Details

Ticker Symbol 047920
Exchange KOSDAQ
Fiscal Year January - December
Reporting Currency KRW
SIC Code 2834

Key Executives

Name Position
Jae-hyeong Park Chief Executive Officer